Akèy › Skleroz an milti pwogresif kwonik
Etid klinik pou Skleroz an milti pwogresif kwonik ap rekrite nan Etazini
18 etid pou Skleroz an milti pwogresif kwonik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- St. Louis, MO4 etid
- Chicago, IL4 etid
- Memphis, TN4 etid
- Orlando, FL4 etid
- Kansas City, KS3 etid
- Tampa, FL3 etid
- Greenville, SC3 etid
- Scottsdale, AZ3 etid
- Burbank, CA3 etid
- Columbus, OH3 etid
Pa eta
- Arizona4 etid
- Florid4 etid
- Georgia3 etid
- Illinois5 etid
- Kalifòni10 etid
- Kansas4 etid
- Michigan4 etid
- Missouri4 etid
- North Carolina3 etid
- Ohio6 etid
- South Carolina3 etid
- Tennessee4 etid
- Texas4 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07609719A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 30, 2026 · NCT07299019A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07840326A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 22, 2026 · NCT07067463Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT07477639Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Ap rekriteFaz 3
Laj 18 a 55 · Tout sèks · Mizajou Sep 16, 2026 · NCT04047628Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 27, 2026 · NCT03109288A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07225504Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Ap rekriteFaz 1/2
Laj 18 a 55 · Tout sèks · Mizajou Jul 2, 2026 · NCT05359653Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Mar 23, 2026 · NCT07139743Intermittent Hypoxia in Persons With Multiple Sclerosis
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Mar 20, 2026 · NCT06276634A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Feb 27, 2026 · NCT06138132Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Feb 23, 2026 · NCT06390930Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 12, 2026 · NCT07392879Home Based Functional Balance Intervention for Multiple Sclerosis
Ap rekrite
Laj 40 a 90 · Tout sèks · Mizajou Jan 21, 2026 · NCT07355387"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 31, 2025 · NCT07222618Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Ap rekrite
Laj 22 a 75 · Tout sèks · Mizajou Sep 24, 2025 · NCT05964829MS-ResearchBiomarkerS
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2024 · NCT05204459Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.